Worldwide Provides the Perfect Blend of Investigative Rigor and Patient Care for Your Duchenne Muscular Dystrophy Clinical Trial

Duchenne Muscular dystrophy refers to a group of diseases characterized by progressive weakness and loss of muscle mass. Although current treatments manage symptoms and slow down the disease’s progression, there is no known cure. Because duchenne muscular dystrophy has several discrete manifestations, clinical trial design requires a clear set of valid outcome measures, and patient enrollment requires precise inclusion/exclusion criteria. Due to the degenerative nature of the disease and the related burden on patients, compliance and retention requires attention.

With our long history in neurological disorders and added background in rare diseases, the team at Worldwide Clinical Trials is able to bring the right blend of investigative rigor and patient centricity to your duchenne muscular dystrophy study. We can ensure that patients are given the optimal study environment to enable them to remain compliant. We balance this patient centricity with strong relationships with investigator sites so that staff are well trained and empowered to communicate their logistical requirements to the trial management team. This collaborative approach ensures best results for quantity and quality of study data.